Lloyd J. Payne, PhD


Lloyd is a drug discovery executive and leader with 25 years’ experience the biopharmaceutical industry, and President and CEO of Arrepath.

Lloyd was the founding CEO of Euprotec where from its inception in 2008, he steered the company through substantial growth, working closely with several companies globally before the it was successfully sold to Evotec in 2014 and he became Executive Vice President, Head of Anti-infectives, Evotec.

Prior to founding Euprotec, Lloyd was a medicinal chemist and worked on a range of programs in the oncology, inflammation and infectious disease therapy areas.  Lloyd has acted as a scientific advisor to several biotech companies in the anti-infectives space and is a current member of the specialist anti-infective investment funds, the Novo Foundation REPAIR Impact Fund and the AMR Action Fund.